Los Angeles Capital Management
BCRX icon

Los Angeles Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Los Angeles Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
1,287
-47,613
-97% -$431K ﹤0.01% 1899
2026
Q1 		$466K Sell
48,900
-306,155
-86% -$2.38M ﹤0.01% 893
2025
Q4 		$2.57M Buy
355,055
+45,945
+15% +$332K 0.01% 399
2025
Q3 		$2.35M Buy
309,110
+210,064
+212% +$1.75M 0.01% 463
2025
Q2 		$887K Sell
99,046
-2,332
-2% -$21.7K ﹤0.01% 678
2025
Q1 		$760K Buy
101,378
+190
+0.2% +$1.53K ﹤0.01% 641
2024
Q4 		$761K Buy
101,188
+14,655
+17% +$111K ﹤0.01% 705
2024
Q3 		$658K Sell
86,533
-11,044
-11% -$84K ﹤0.01% 785
2024
Q2 		$603K Buy
97,577
+7,963
+9% +$43.9K ﹤0.01% 806
2024
Q1 		$455K Buy
89,614
+36,284
+68% +$204K ﹤0.01% 903
2023
Q4 		$319K Buy
53,330
+20,202
+61% +$117K ﹤0.01% 1000
2023
Q3 		$235K Buy
33,128
+506
+2% +$3.64K ﹤0.01% 1031
2023
Q2 		$230K Buy
+32,622
New +$262K ﹤0.01% 1086
2022
Q4 		– Sell
-14,285
Closed -$180K – 1192
2022
Q3 		$180K Buy
+14,285
New +$184K ﹤0.01% 1180
2021
Q2 		– Sell
-30,950
Closed -$315K – 1540
2021
Q1 		$315K Sell
30,950
-147,375
-83% -$1.52M ﹤0.01% 1417
2020
Q4 		$1.33M Buy
178,325
+48,855
+38% +$252K 0.01% 812
2020
Q3 		$445K Buy
129,470
+46,515
+56% +$199K ﹤0.01% 1128
2020
Q2 		$395K Sell
82,955
-36,225
-30% -$145K ﹤0.01% 1197
2020
Q1 		$238K Buy
119,180
+30,130
+34% +$83K ﹤0.01% 1130
2019
Q4 		$307K Buy
+89,050
New +$224K ﹤0.01% 1124
2017
Q4 		– Sell
-25,170
Closed -$132K – 1318
2017
Q3 		$132K Buy
+25,170
New +$129K ﹤0.01% 1276
2015
Q2 		– Sell
-12,860
Closed -$116K – 1206
2015
Q1 		$116K Buy
+12,860
New +$133K ﹤0.01% 1187

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Los Angeles Capital Management's BCRX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 97% in Q2 2026, selling an estimated $431K and leaving 1,287 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Los Angeles Capital Management first reported a position in BCRX in Q1 2015 and has held it in 22 quarters since. The position peaked at $2.57M in Q4 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Los Angeles Capital Management held 1,287 shares of BioCryst Pharmaceuticals worth $12.9K as of Q2 2026.
  • Los Angeles Capital Management sold 47,613 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $431K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1899 holding.
  • Los Angeles Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2015 and has held it in 22 quarters since.
  • Los Angeles Capital Management's BioCryst Pharmaceuticals position peaked at $2.57M in Q4 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.